Cargando…

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5

Detalles Bibliográficos
Autores principales:	Rahimi, Farid, Talebi Bezmin Abadi, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343086/ https://www.ncbi.nlm.nih.gov/pubmed/35926828 http://dx.doi.org/10.1016/j.ijsu.2022.106806

Ejemplares similares

‘The end’ – or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants
por: Rahimi, Farid, et al.
Publicado: (2023)

The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Detection of the XE subvariant of SARS-CoV-2: A perspective
por: Rahimi, Farid, et al.
Publicado: (2022)

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
por: Jian, Fanchong, et al.
Publicado: (2022)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Challenges of managing the asymptomatic carriers of SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
por: Park, Kyemyung, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

Highly contagious but less severe COVID-19 caused by new SARS-CoV-2 sublineages may abate the pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012/01
por: Rahimi, Farid, et al.
Publicado: (2021)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Emergence of the Delta Plus variant of SARS-CoV-2 in Iran
por: Rahimi, Farid, et al.
Publicado: (2021)

Omicron: A highly transmissible SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Analytical Sensitivity of Lateral Flow Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75
por: Mackenzie, Charlene, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Case-finding: Fast, Available, and Efficient Font-line Diagnostics for SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection
por: Chen, Xiaosu, et al.
Publicado: (2023)

Cryo-EM structures of SARS-CoV-2 BA.2-derived subvariants spike in complex with ACE2 receptor
por: Li, Yaning, et al.
Publicado: (2023)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
por: Li, Mingxi, et al.
Publicado: (2022)

The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2021)

A Commentary on “Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt” (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

SARS-CoV-2 Lambda (C.37): An emerging variant of concern?
por: Darvishi, Mohammad, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qqbg5d8oi2karet498nfa10kc